N,N-Bis(2-chloroethyl)-L-alanine | 776230-39-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N,N-Bis(2-chloroethyl)-L-alanine
• 英文别名: (2S)-2-[bis(2-chloroethyl)amino]propanoic acid
• CAS: 776230-39-8
• 化学式: C₇H₁₃Cl₂NO₂
• 分子量: 214.09
• InChiKey: NRIFCKOLJVDPTP-LURJTMIESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  12
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Process for making chiral 1,4-disubstituted piperazines
  申请人：Wyeth

  公开号：US20030208075A1

  公开（公告）日：2003-11-06

  A process for a stereoselective preparation of novel chiral nitrogen mustard derivatives useful in synthesizing optically active 1,4-disubstituted piperazines of formula: 1 wherein R, Ar, and Q are defined as set forth herein, and intermediate compounds therefor. The 1,4-disubstituted piperazines act as 5HT1A receptor binding agents useful in the treatment of Central Nervous System (CNS) disorders.

  一种用于立体选择性制备新型手性氮芥衍生物的方法，用于合成式中的光学活性1,4-二取代哌嗪： 其中R、Ar和Q的定义如本文所述，并且中间化合物。1,4-二取代哌嗪作为5HT1A受体结合剂，在治疗中枢神经系统（CNS）疾病中有用。
• 4-SUBSTITUTED PYRIDIN-3-YL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE
  申请人：Wang Xiaojing

  公开号：US20110059961A1

  公开（公告）日：2011-03-10

  The invention relates to compounds of formula (I) which are useful as kinase inhibitors, more specifically useful as PIM kinase inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same, either alone or in combination, to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

  这项发明涉及到式(I)的化合物，这些化合物可用作激酶抑制剂，更具体地用作PIM激酶抑制剂，因此可用作癌症治疗药物。该发明还涉及到包括这些化合物的组合物，更具体地是包括这些化合物的药物组合物，以及使用这些组合物的方法，无论是单独使用还是结合使用，用于治疗各种癌症和高增殖性疾病，以及使用这些化合物进行体外、体内和体内诊断或治疗哺乳动物细胞或相关病理条件的方法。
• COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF HEMATOPOIETIC MALIGNANCIES
  申请人：Ebens, JR. Allen J.

  公开号：US20100233164A1

  公开（公告）日：2010-09-16

  Combinations of PI3K inhibitor compounds having Formula I and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hematopoietic malignancies. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  具有I式的PI3K抑制剂化合物及其立体异构体、几何异构体、互变异构体、代谢产物和药学上可接受的盐的组合物，可用于治疗造血恶性肿瘤。本文披露了使用这种组合物在哺乳动物细胞中进行体外、体内和原位诊断、预防或治疗此类疾病或相关病理条件的方法。
• DRUG DELIVERY COMPOSITIONS
  申请人：AUSTRALIAN COMMERCIAL RESEARCH & DEVELOPMENT LIMITED

  公开号：EP0491812A1

  公开（公告）日：1992-07-01
• EP0491812A4
  申请人：——

  公开号：EP0491812A4

  公开（公告）日：1992-11-04